Skip to main content
AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)
Loading prices
Back to the NewsWire

Theoaklandpress

Published November 13, 2026 · Updated November 15, 2026

Trump administration will fund new research on controversial psychedelic drug ibogaine

Read the full story at Theoaklandpress

press . PUBLISHED: November 12, 2026 at 1:24 PM EST. Getting your Trinity Audio player ready... By MATTHEW PERRONE, AP Health Writer. WASHINGTON (AP).

Surfaced by 5 Google Alerts

  • Psychedelic press release
  • Ibogaine
  • Psychedelic crime
  • Psychedelics south america
  • LSD